Cited 171 times in
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2015-01-06T16:32:29Z | - |
dc.date.available | 2015-01-06T16:32:29Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0171-5216 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/98299 | - |
dc.description.abstract | PURPOSE: Cisplatin plus 5-fluorouracil has been globally accepted as a standard regimen for the treatment for advanced gastric cancer. However, cisplatin has several disadvantages, including renal toxicity and the need for admission. S-1 plus cisplatin has become a standard treatment for advanced gastric cancer in East Asia. This phase III study was designed to evaluate the potential benefits of adding docetaxel to S-1 without a platinum compound in patients with advanced gastric cancer. METHODS: Patients were randomly assigned to receive docetaxel plus S-1 or S-1 alone. The docetaxel plus S-1 group received docetaxel on day 1 and oral S-1 on days 1-14 of a 21-day cycle. The S-1 alone group received oral S-1 on days 1-28 of a 42-day cycle. The primary end point was overall survival. RESULTS: Of the 639 patients enrolled, 635 were eligible for analysis. The median overall survival was 12.5 months in the docetaxel plus S-1 group and 10.8 months in the S-1 alone group (p = 0.032). The median progression-free survival was 5.3 months in the docetaxel plus S-1 group and 4.2 months in the S-1 alone group (p = 0.001). As for adverse events, neutropenia was more frequent in the docetaxel plus S-1 group, but remained manageable. CONCLUSION: As first-line treatment for advanced gastric cancer, docetaxel plus S-1 significantly improves median overall and progression-free survival as compared with S-1 alone. (ClinicalTrials.gov number: NCT00287768). | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 319~328 | - |
dc.relation.isPartOf | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenocarcinoma/drug therapy | - |
dc.subject.MESH | Adenocarcinoma/mortality* | - |
dc.subject.MESH | Adenocarcinoma/pathology | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Cisplatin/administration & dosage | - |
dc.subject.MESH | Drug Combinations | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Follow-Up Studies | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Neoplasm Recurrence, Local/drug therapy | - |
dc.subject.MESH | Neoplasm Recurrence, Local/pathology | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Oxonic Acid/administration & dosage | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Stomach Neoplasms/drug therapy | - |
dc.subject.MESH | Stomach Neoplasms/mortality* | - |
dc.subject.MESH | Stomach Neoplasms/pathology | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Taxoids/administration & dosage | - |
dc.subject.MESH | Tegafur/administration & dosage | - |
dc.subject.MESH | Young Adult | - |
dc.title | Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START) | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Wasaburo Koizumi | - |
dc.contributor.googleauthor | Yeul Hong Kim | - |
dc.contributor.googleauthor | Masashi Fujii | - |
dc.contributor.googleauthor | Hoon Kyo Kim | - |
dc.contributor.googleauthor | Hiroshi Imamura | - |
dc.contributor.googleauthor | Kyung Hee Lee | - |
dc.contributor.googleauthor | Takuo Hara | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.contributor.googleauthor | Taroh Satoh | - |
dc.contributor.googleauthor | Jae Yong Cho | - |
dc.contributor.googleauthor | Hisashi Hosaka | - |
dc.contributor.googleauthor | Akihito Tsuji | - |
dc.contributor.googleauthor | Akinori Takagane | - |
dc.contributor.googleauthor | Mikito Inokuchi | - |
dc.contributor.googleauthor | Kazuaki Tanabe | - |
dc.contributor.googleauthor | Tatsuya Okuno | - |
dc.contributor.googleauthor | Mariko Ogura | - |
dc.contributor.googleauthor | Kazuhiro Yoshida | - |
dc.contributor.googleauthor | Masahiro Takeuchi | - |
dc.contributor.googleauthor | Toshifusa Nakajima | - |
dc.identifier.doi | 10.1007/s00432-013-1563-5 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A03899 | - |
dc.relation.journalcode | J01283 | - |
dc.identifier.eissn | 1432-1335 | - |
dc.identifier.pmid | 24366758 | - |
dc.subject.keyword | Advanced gastric cancer | - |
dc.subject.keyword | Chemotherapy | - |
dc.subject.keyword | S-1 | - |
dc.subject.keyword | Docetaxel | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.citation.volume | 140 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 319 | - |
dc.citation.endPage | 328 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, Vol.140(2) : 319-328, 2014 | - |
dc.identifier.rimsid | 51823 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.